tumor activity, including durable responses, in patients with mBCC after progression or intolerance on HHI therapy. Acknowledgements Editorial acknowledgment: Medical writing support was provided by Cindi Hoover, PhD of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc. and Sanofi.

Ethics Approval The study protocols and all amendments were approved by the institutional review board at each participating study site. The study was conducted in accordance with the principles of the Declaration of Helsinki and with Good Clinical Practice guidelines as defined by the International Conference on Harmonization. All patients provided written informed consent before enrollment.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0428

LONG-TERM ANALYSIS OF MASTERKEY-265 PHASE 1B TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) PLUS PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE STAGE IIIIB–IVM1C MELANOMA

1Georgina Long*, 2Reinhard Dummer, 3Douglas Johnson, 4Olivier Michielin, 5Salvador Martin-Aldana, 6Sheryl Treichel, 7Edward Chan, 8Scott Diele, 9Antoni Ribas, 10Melanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, Australia; 11University Hospital of Zurich, Zurich, SC, Switzerland; 12Vanderbilt University Medical Center, Nashville, TN, USA; 13Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 14Clínica Universidad de Navarra (CUN), Medical School of the University of Navarra, Pamplona, Spain; 15Amgen Inc., Thousand Oaks, CA, USA; 16Merck and Co., Inc., Kenilworth, NJ, USA; 17University of California at Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

Background Previous findings from the MASTERKEY-265 phase 1b study showed that the combination of T-VEC and pembrolizumab was well tolerated and produced a high complete response (CR) rate of 43% in patients with advanced melanoma.1 The 3-year progression-free survival (PFS) and overall survival (OS) rates at that time were 53.6% and 71%, respectively. Here, we report the results of the long-term follow-up efficacy analyses.

Methods The MASTERKEY-265 phase 1b trial (NCT02263508) was an open-label, single-arm study that enrolled patients who had unresectable, stage IIIB-IVM1c melanoma with injectable, measurable lesions and no prior systemic treatment. T-VEC was administered intravenously at the time of surgery. Pembrolizumab (200 mg) was administered intravenously Q2W beginning on day 1 of week 1. Pembrolizumab (200 mg) was administered intravenously Q2W beginning on day 1 of week 1. The maximum treatment period was 2 years. The primary endpoint was dose-limiting toxicities; key secondary endpoints included objective response rate and PFS per modified irRC, OS, and safety.

Results As of the data cutoff (Mar 2, 2020), all 21 patients enrolled were off treatment; 6 died and 15 are in long-term follow-up. The median follow-up time was 58.6 months (range: 1.4–61.6). The CR rate remained 43% (9/21 patients). Twelve of the 13 responders (92.3%) are still in follow-up, including all 9 patients with a CR. Median duration of response was not reached (range: 2.8+–54.3+ months). Median PFS and OS were not reached at the data cutoff. KM estimates of 4-year PFS and OS rates were 55.9% and 71.4%, respectively, which have held stable since the 3-year analysis. Patients who achieved a CR or partial response had better OS (p=0.0056) compared to those who did not respond. Median OS for non-responders was 24.4 months and was not reached for responders. No additional safety signals were detected.

Conclusions At almost 5 years of follow-up, median PFS and OS were not reached for patients treated with the combination of TVEC and pembrolizumab in this phase 1b study of unresectable metastatic melanoma. 92% of responders remained in response with improved OS observed in responders compared with non-responders. The corresponding randomized phase 3 trial has completed enrollment and is currently ongoing.

Trial Registration NCT02263508

Ethics Approval The study was approved by the Ethics Board of each institution involved in this study and can be produced upon request.

REFERENCE

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0429

A PHASE II STUDY OF NIVOLUMAB + BMS-986016 (RELATLIMAB) IN PATIENTS WITH METASTATIC UVEAL MELANOMA (UM) (CA224–094)

1Jose Lutzky*, 2Jose Lutzky, 3Lynn Feun, 4William Harbour. 1University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA; 2U of Miami Bascom Palmer Eye Institute, Miami, FL, USA

Background Fifty percent of patients with uveal melanoma (UM) develop metastatic disease, surviving 6–12 months from metastatic diagnosis. Liver-directed therapies, immunotherapy, targeted therapy, and chemotherapy have limited activity. Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint receptor associated with decreased T-cell effector function and tumor escape. Preclinical models have shown that dual inhibition of LAG-3 and PD-1 blockade generates synergistic anti-tumor activity.1 In uveal melanoma, CD8+ T cells express the checkpoint receptor LAG3 to a greater extent than PD1 or CTLA4.2 3 This recent discovery nomi- nates LAG3 as a potential candidate for checkpoint inhibitor immunotherapy in UM.

Methods This is an open-label, single arm, single site investiga- tor-initiated phase II study. Based on Simon two-stage mini- max design, 13 patients will be enrolled in Stage 1. If at least one response is noted, the study will proceed to Stage 2 and enroll additional 14 patients. The null hypothesis will be rejected if 4 or more responses are observed among 27 patients. This design achieves 5% type I error and 80% power when the true ORR is 20%.Main eligibility criteria includes patients with biopsy proven metastatic uveal melanoma, previously untreated with PD-1, CTLA-4 and/or LAG-3 blocking antibodies and in good performance status.Enrolled patients will be treated in the outpatient setting. Nivolumab 480 mg will be mixed in the same bag with relatlimab 160 mg and administered intravenously over 60 minutes every 4 weeks until disease progression or intolerable toxicity for up to 24 months.The primary endpoint is best objective response rate (ORR). Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), median duration of response (mDOR), and adverse events...
Correlative studies will evaluate pre- and post-treatment characteristics of T cells in the tumor microenvironment and blood.

Results N/A

Conclusions N/A

Ethics Approval The study was approved by the University of Miami Sylvester Cancer Center PRMC #20200847

Consent N/A

REFERENCES


http://dx.doi.org/10.1136/jitc-2020-SITC2020.0430

PROSPECTIVE, RANDOMIZED TRIAL OF THE TUMOR LYSATE, PARTICLE ONLY VACCINE COMPARED TO THE TUMOR LYSATE, PARTICLE-LOADED, DENDRITIC CELL VACCINE TO PREVENT RECURRENCE FOR RESECTED STAGE III/IV MELANOMA

1Patrick McCarthy*, 1Lexy Adams, 1Robert Chick, 1Guy Clifton, 1Timothy Vreeland, 1Anne O’Shea, 1Phillip Kemp Bohn, 1Annelies Hickeron, 1Jessica Camp, 1John Myers, 1Tommy Brown, 1Diane Hale, 2Mark Fairies, 2John Hyngstrom, 3Adam Berger, 3James Jakub, 4Jeffrey Susan, 4Montaser Shaheen, 5Thomas Wagner, 6George Peoples, 7Brooke Army Medical Center, San Antonio, TX, USA; 8The Los Angeles Angeles Clinic, CA, USA; 9University of Utah, Salt Lake City, UT, USA; 10Thomas Jefferson University, Philadelphia, PA, USA; 11Mayo Clinic, Rochester, MN, USA; 12University of Cincinnati, Cincinnati, OH, USA; 13University of Arizona, Phoenix, AZ, USA; 14Orbis Health Solutions, Greenville, SC, USA; 15Cancer Vaccine Development Group, San Antonio, TX, USA

Background The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is safe and effective in improving 24 and 36-month disease-free survival (DFS) in patients (pts) with resected stage III/IV melanoma who completed the primary vaccine series. The tumor lysate, particle only (TLPO) vaccine has been developed to accelerate production by omitting DC isolation and ex vivo loading in favor of in vivo phagocytosis of the TL-loaded particles. We are currently conducting a randomized and double-blind trial of the TLPO vs TLPLDC to improve DFS and overall survival (OS) in patients with resected late stage melanoma.

Methods Patients with stage III/IV melanoma who were clinically disease-free after standard of care therapies were randomized to receive TLPO vs TLPLDC (2:1) as a continuation of the phase Ib trial comparing TLPLDC vs placebo (2:1). For the TLPLDC vaccine, autologous TL was loaded into yeast cell wall particles (YCWP) which were then phagocytized by isolated autologous DC ex vivo. For the placebo DC were loaded with empty YCWP. For TLPO, the autologous TL-loaded YCWP were coated with a chemoattractant and injected intradermally for in vivo phagocytosis. Some patients in the TLPLDC arm received G-CSF prior to DC harvest to minimize blood draw (60 mL instead of 120 mL without G-CSF). For all arms, six vaccine/placebo doses were administered intradermally at 0, 1, 2, 6, 12, and 18 mos. Data was analyzed by an intention-to-treat (ITT) analysis for DFS and OS by the Kaplan-Meier method and compared by log-rank test.